PT  - JOURNAL ARTICLE
AU  - Levi, Hoste
AU  - Ruben, Van Paemel
AU  - Filomeen, Haerynck
TI  - Multisystem inflammatory syndrome in children related to COVID-19: A systematic review
AID  - 10.1101/2020.08.17.20173641
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.17.20173641
4099  - http://medrxiv.org/content/early/2020/08/18/2020.08.17.20173641.1.short
4100  - http://medrxiv.org/content/early/2020/08/18/2020.08.17.20173641.1.full
AB  - Importance In April 2020, multiple reports of an association between a hyperinflammatory, Kawasaki-like condition and SARS-CoV-2 were published and termed as pediatric inflammatory multisystem syndrome (PIMS) or multisystem inflammatory syndrome (MIS). A thorough characterization of this syndrome (demographics, presentation, diagnosis, and outcome) is currently lacking.Objective We aimed to perform a systematic review of published cases of this novel multisystem inflammatory syndrome in children associated with COVID-19.Evidence review A literature search of Pubmed, Embase, BioRxiv, MedRxiv and COVID-19 specific research repositories (Cochrane COVID-19 Study Register and the World Health Organization (WHO) COVID-19 Global Research Database) was conducted from December 30th, 2019 to June 30th, 2020. Publications describing inflammatory syndromes associated with COVID-19 were included. Of 333 unique publications, 229 records were excluded based on title and abstract. After screening the full text, 40 observational studies and case reports were included, comprising 687 cases (published between May 9th, 2020 and June 30th, 2020).Findings In contrast to classic Kawasaki disease, epidemiological enrichment for adolescents (median age 9 [6.0-12.3]) and ethnic minorities (35.8% black and 24.5% Hispanic/Latino) was observed. There was a male predominance (59.1%). Apart from obesity (24.4%), pre-existing conditions were infrequent. The majority suffered from gastrointestinal (87.2%) and cardiocirculatory (79.2%) manifestations. Respiratory symptoms (51.2%) were less frequent. Over half of patients (56.3%) presented with hemodynamic shock, and critical care interventions were often necessary (inotropics (56.5%), mechanical ventilation (22.9%), non-invasive ventilation (30.6%), extracorporal membrane oxygenation (ECMO;4.5%)). Anti-SARS-CoV-2 IgG and RT-PCR were positive in respectively 69.4% and 36.7%. Eleven deaths were reported (1.6%). The RCPCH case definition proved to be most comprehensive comprising all single cases. In contrast, WHO and CDC MIS definitions are more stringent, with the CDC case definition often missing severe cases requiring intensive care (n = 33 out of 95 cases).Conclusions and Relevance This novel pediatric multisystem hyperinflammatory condition, associated with COVID-19, is characterized by a severe and heterogeneous disease spectrum. Despite frequent intensive care interventions, mortality rate was low and short-term outcome favorable. Long-term follow-up of possible chronic complications and additional clinical research, to elucidate the underlying immunological pathogenesis and possible genetic predisposition is crucial.Question How is the novel pediatric multisystem inflammatory condition associated with coronavirus disease 2019 (COVID-19) characterized?Findings This systematic review of 40 studies, comprising 687 cases, represents the heterogeneous spectrum of this novel pediatric disease related to COVID-19, including contrasting features with previously-described hyperinflammatory conditions. Adolescents and particular racial/ethnic minorities are affected more. Gastrointestinal and cardiocirculatory manifestations are often found, along with critical care interventions. Nevertheless, only 11 deaths are reported.Meaning This novel condition has variable severity but good short-term outcome. Uniform case definitions are required to guide future (preferably controlled) research on epidemiological clustering, immunopathology, and long-term prognosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementL. H. was funded by the VIB Grand Challenge project. R.V.P was funded by a predoctoral fellowship from the Research Foundation Flanders (FWO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data will be made available on Github (https://github.com/rmvpaeme/PIMS_MISC_SR) after peer review. The processed data has been added as a supplementary file.